|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-3-3
|
|
pubmed:abstractText |
One hundred fifty patients with sustained virologic response (SVR) after treatment of chronic hepatitis C were enrolled in a long-term clinical follow-up study; patients were followed for 5 years for liver-related outcomes and evidence of biochemical or virologic relapse. Patients with stage 2 or greater fibrosis on pretreatment biopsy were invited to undergo a long-term follow-up biopsy after their fourth year of follow-up. One hundred twenty-eight patients (85%) were followed through their fourth year, and long-term follow-up biopsies were obtained from 60 patients (40%). Forty-nine patients had paired pretreatment and long-term follow-up biopsies blindly rescored. Forty of these patients (82%) had a decrease in fibrosis score, and 45 (92%) had a decrease in combined inflammation score. Ten patients (20%) had normal or nearly normal livers on long-term follow-up biopsy. Two patients with pretreatment cirrhosis developed hepatocellular carcinoma (HCC), and one died. All the other patients with pretreatment cirrhosis or advanced fibrosis had improved fibrosis scores on long-term follow-up biopsy. No patient had conclusive evidence of virologic relapse. Three patients had persistently elevated alanine aminotransferase levels; two of these had new liver disease. CONCLUSION: In a cohort of 150 patients with SVR followed for 5 years, the majority of patients had good outcomes. Serum virologic relapse was not seen, but two patients with pretreatment cirrhosis developed HCC, and one died. In a blind rescoring of 49 paired pretreatment and long-term follow-up biopsies, 82% improved fibrosis scores and 92% improved at least one component of inflammation. A minority of patients had normal or nearly normal liver tissue on long-term follow-up biopsy. Patients with cirrhosis pretreatment are at a low but real risk of HCC after SVR.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19072828-10613753,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19072828-10744587,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19072828-10996636,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19072828-11984517,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19072828-11984538,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19072828-12883494,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19072828-15361504,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19072828-18025443,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19072828-7694894,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19072828-9382365,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19072828-9755252,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19072828-9807989
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1527-3350
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
49
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
729-38
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19072828-Adult,
pubmed-meshheading:19072828-Aged,
pubmed-meshheading:19072828-Alanine Transaminase,
pubmed-meshheading:19072828-Antiviral Agents,
pubmed-meshheading:19072828-Aspartate Aminotransferases,
pubmed-meshheading:19072828-Biopsy,
pubmed-meshheading:19072828-Drug Therapy, Combination,
pubmed-meshheading:19072828-Female,
pubmed-meshheading:19072828-Follow-Up Studies,
pubmed-meshheading:19072828-Genotype,
pubmed-meshheading:19072828-Hepacivirus,
pubmed-meshheading:19072828-Hepatitis C,
pubmed-meshheading:19072828-Humans,
pubmed-meshheading:19072828-Interferon-alpha,
pubmed-meshheading:19072828-Liver,
pubmed-meshheading:19072828-Male,
pubmed-meshheading:19072828-Middle Aged,
pubmed-meshheading:19072828-Polyethylene Glycols,
pubmed-meshheading:19072828-Recombinant Proteins,
pubmed-meshheading:19072828-Ribavirin,
pubmed-meshheading:19072828-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients.
|
|
pubmed:affiliation |
Department of Internal Medicine, Division of Gastroenterology, Saint Louis University Liver Center, St Louis, MO, USA. georgesl@slu.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
